The publication highlights expert perspectives on the latest developments in pertussis prevention and the potential advantages of a new recombinant pertussis-only vaccine.

Key Highlights

• Pertussis remains a significant public health challenge despite high vaccination coverage.
• Australia and New Zealand have experienced recurring pertussis outbreaks, highlighting the need for improved protection strategies.
• The publication discusses a new recombinant pertussis-only vaccine developed using genetically detoxified pertussis toxin technology.
• Expert authors review the potential for strong and durable immune responses against pertussis.
• The article explores possible benefits for maternal immunization, adolescent and adult boosters, healthcare workers, and older adults.
• The vaccine’s antigen-specific approach may provide greater flexibility for future immunization programs.
• Experts discuss how this innovation could help address unmet needs in pertussis prevention in Australia, New Zealand, and potentially other countries.

Read the full article: vaccines